argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

argenx SE announced topline results from the ADVANCE-SC study evaluating VYVGART Hytrulo in adults with primary immune thrombocytopenia.